High-dose immunoglobulin preparations improve survival in a CLP-induced rat model of sepsis

Langenbeck's Archives of Surgery

Volumn 397, Issue 3, 2012, Pages 457-465

  Yoshikawa, Takahisa ^a   Takeuchi, Hiroya ^a   Suda, Koichi ^a   Miyasho, Taku ^b   Yamada, Shingo ^c   Okamoto, Minoru ^b   Kawamura, Yoshio ^b   Maruyama, Ikuro ^d   Kitajima, Masaki ^a   Kitagawa, Yuko ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b RAKUNO GAKUEN UNIVERSITY   (Japan)

^c SHINO TEST CORPORATION   (Japan)

^d KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

Cecal ligation and puncture model; Endotoxin; HMGB1; Immunoglobulin; Sepsis

Indexed keywords

CREATININE; ENDOTOXIN; HIGH MOBILITY GROUP B1 PROTEIN; LACTATE DEHYDROGENASE; NITROGEN; SULFONATED IMMUNOGLOBULIN; UREA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOSE RESPONSE; DRUG MEGADOSE; HISTOPATHOLOGY; LACTATE DEHYDROGENASE BLOOD LEVEL; LOW DRUG DOSE; MALE; NONHUMAN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT; SEPSIS; SURVIVAL RATE; UPREGULATION; UREA NITROGEN BLOOD LEVEL;

ANIMALS; CECUM; CYTOKINES; DISEASE MODELS, ANIMAL; HIGH MOBILITY GROUP PROTEINS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; KIDNEY; LIGATION; LUNG; MALE; PUNCTURES; RATS; RATS, SPRAGUE-DAWLEY; SEPSIS; SHOCK, SEPTIC;

EID: 84859818648     PISSN: 14352443     EISSN: 14352451     Source Type: Journal    
DOI: 10.1007/s00423-011-0878-4     Document Type: Article

References (34)

1. Bone RC, Sprung CL, Sibbald WJ (1992) Definitions for sepsis and organ failure. Crit Care Med 20:724-726
2. Schlichting D, McCollam JS (2007) Recognizing and managing severe sepsis: a common and deadly treat. South Med J 100:594-600 (Pubitemid 46956541)
3. Andrews P, Azoulay E, Antonelli M, Brochard L, Brun-Buisson C, Dobb G, Fagon JY, Gerlach H, Groeneveld J, Mancebo J, Metnitz P, Nava S, Pugin J, Pinsky M, Radermacher P, Richard C, Tasker R (2006) Year in review in intensive care medicine, 2005. II. Infection and sepsis, ventilator-associated pneumonia, ethics, hematology and hemostasis, ICU, organization and scoring, brain, injury. Intensiv Care Med 32:380-390 (Pubitemid 43289646)
4. Andrews P, Azoulay E, Antonelli M, Brochard L, Brun-Buisson C, Dobb G, Fagon JY, Gerlach H, Groeneveld J, Mancebo J, Metnitz P, Nava S, Pugin J, Pinsky M, Radermacher P, Richard C, Tasker R, Vallet B (2005) Year in review in intensive care medicine, 2004. I. Respiratory failure, infection, and sepsis. Intensiv Care Med 31:28-40 (Pubitemid 40178742)
5. Witchterman KA, Baue AE, Chaudry IH (1980) Sepsis and septic shock - a review of laboratory models and a proposal. J Surg Res 29:189-201 (Pubitemid 10039498)
6. Baker CC, Chaudry IH, Gaines HO, Baue AE (1983) Evaluation of factors affecting mortality rate after sepsis in murine cecal ligation and puncture model. Surgery 94:331-335 (Pubitemid 13043132)
7. Anton EO, Quintela AG, Soto AL, Ben SL, Llovo J, Perez LF (2001) Cecal ligation and puncture as a model of sepsis in the rat: influence of the puncture size on mortality, bacteremia, endotoxemia and tumor necrosis factor alpha level. Eur Surg Res 33:77-79 (Pubitemid 32588804)
8. Heuer JG, Bailey DL, Sharma GR, Zhang T, Ding C, Ford A, Stephens EJ, Holmes KC, Grubbs RL, Fynboe KA, Chen YF, Jakubowski JA (2004) Cecal ligation and puncture with total parenteral nutrition: a clinically relevant model of the metabolic, hormonal, and inflammatory dysfunction associated with critical illness. J Surg Res 121:178-186 (Pubitemid 39387458)
9. Suda K, Takeuchi H, Hagiwara T, Miyasho T, Okamoto M, Kawasako K, Yamada S, Suganuma K, Wada N, Saikawa Y, Fukunaga K, Funakoshi Y, Hashimoto S, Yokota H, Maruyama I, Ishizaka A, Kitagawa Y (2010) Neutrophil elastase inhibitor improves survival of rats with clinically relevant sepsis. Shock 33:526-531
10. Nimmerjahn F, Raventch JV (2008) Anti-inflammatory actions of intravenous immunoglobulin. Annu Rev Immunol 26:513-533 (Pubitemid 351600384)
11. Negi VS, Elluru S, Sibéril S, Graff-Dubois S, Mouthon L, Kazatchkine MD, Lacroix-Desmazes S, Bayry J, Kaveri SV (2007) Intravenous immunoglobulin: an update on the clinical use and mechanism of action. J Clin Immunol 27:233-245 (Pubitemid 46790823)
12. Prins C, Gelfand EW, French LE (2007) Intravenous immunoglobulin: properties, mode of action and practical use in dermatology. Acta Derm Venereol 87:206-218 (Pubitemid 47226887)
13. Bussel JB (2002) Another interaction of the FcR system with IVIG. Thromb Haemost 88:890-891
14. Crow AR, Song S, Siragam V, Lazarus AH (2006) Mechanisms of action of intravenous immunoglobulin in the treatment of immune thrombocytopenia. Pediatr Blood Cancer 47:10-13
15. Turgeon AF, Hutton B, Fergusson DA, McIntyre L, Tinmouth AA, Cameron DW, Hébert PC (2007) Meta-analysis: intravenous immunoglobulin in critically ill adult patients with sepsis. Ann Intern Med 146:193-203 (Pubitemid 351650633)
16. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, Frazier A, Yang H, Ivanova S, Borovikova L, Manogue KR, Faist E, Abraham E, Andersson J, Andersson U,Molina PE, AbumradNN, Sama A, Tracey KJ (1999)HMG-1 as a late phase mediator of endotoxin lethality in mice. Science 285:248-251 (Pubitemid 29329996)
17. Abraham E, Arcaroli J, Carmody A, Wang H, Tracey KJ (2000) Cutting edge: HMG-1 as a mediator of acute lung inflammation. J Immunol 165:2950-2954
18. Wang H, Yang H, Tracey KJ (2004) Extracellular role of HMGB1 in inflammation and sepsis. J Intern Med 255:320-331 (Pubitemid 38324549)
19. Ueno H, Matsuda T, Hshimoto S, Amaya F, Kitamura Y, Tanaka M, Kobayashi A, Maruyama I, Yamada S, Hasegawa N, Soejima J, Koh H, Ishizaka A (2004) Contributions of high mobility group box protein in experimental and clinical acute lung injury. Am J Respir Crit Care Med 170:1310-1316 (Pubitemid 39657195)
20. Suda K, Kitagawa Y, Ozawa S, Saikawa Y, Ueda M, Ebina M, Yamada S, Hashimoto S, Fukata S, Abraham E, Maruyama I, Kitajima M, Ishizaka A (2006) Anti-high-mobility group box chromosomal protein 1 antibodies improve survival of rats with sepsis. World J Surg 30:1755-1762 (Pubitemid 44411235)
21. Yamada S, Inoue K, Yakabe K, Imaizumi H, Maruyama I (2003) High mobility group protein 1 (HMGB1) quantified by ELISA with a monoclonal antibody that does not cross-react with HMGB2. Clin Chem 49:1535-1537 (Pubitemid 37011747)
22. Hatada T, Wada H, Nobori T, Okabayashi K, Maruyama K, Abe Y, Uemoto S, Yamada S, Maruyama I (2005) Plasma concentrations and importance of high mobility group box protein in the prognosis of organ failure in patients with disseminated intravascular coagulation. Thromb Haemost 94:975-979 (Pubitemid 41645937)
23. Sunden-Culberg J, Norrby-Teglund A, Rouhiainen A, Rauvala H, Herman G, Tracey KJ, Lee ML, Andersson J, Tokics L, Treutiger CJ (2005) Persistent elevation of high mobility group box-1 protein (HMGB1) in patients with severe sepsis and septic shock. Crit Care Med 33:564-573 (Pubitemid 40365558)
24. Werdan K, Pilz G, Bujdoso O et al (2007) Score-based immunoglobulin G therapy of patients with sepsis. Crit Care Med 35:2693-2701 (Pubitemid 350175763)
25. Laupland KB, Kirkpatrick AW, Delaney A et al (2007) Polyclonal intravenous immunoglobulin for the treatment of severe sepsis and septic shock in critically ill adults: a systemic review and meta-analysis. Crit Care Med 35:2686-2692 (Pubitemid 350175762)
26. Rodriguez A, Rello J, Neira J, Maskin B, Ceraso D, Vasta L, Palizas F (2005) Effects of high-dose of intravenous immunoglobulin and antibiotics on survival for severe sepsis undergoing surgery. Shock 23:298-304 (Pubitemid 40463621)
27. Hoffmann JN, Fertmann JM, Vollmar B, Brigitte V, Matthias LW, Karl JW, Michael MD (2008) Immunoglobulin M-enriched human intervenes immunoglobulins reduce leukocyte-endothelial cell interactions and attenuate microvascular perfusion failure in normotensive endotoxemia. Shock 28:133-139
28. Fabrizio K, Groner A, Boes M, Pirofski LA (2007) A human monoclonal immunoglobulin M reduces bacteremia and inflammation in a mouse model of systemic pneumococcal infection. Clin Vaccine Immunol 14:382-390 (Pubitemid 46732548)
29. Shoenfeld H, Fishman P (1999) Gamma-globulin inhibits tumor spread in mice. Int Immunol 11:1247-1251
30. Felts AG, Giridhar G, Grainger DW, Slunt JB (1999) Efficacy of locally delivered polyclonal immunoglobulin against Pseudomonas aeruginosa infection in a murine burn wound model. Burns 25:415-423 (Pubitemid 29351988)
31. Iwamura Y, Tsumoto K, Sakou M, Yoshikawa H, Tashiro A, Otomo S (1978) Effect of S-sulfonation on antibody titer of immunoglobulin. Rinsho To Kenkyu 55:1900-1907
32. Bruhns P, Samuelsson A, Pollard JW, Ravetch JV (2003) Colony stimulating factor-I-dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease. Immunity 18:573-581 (Pubitemid 36513638)
33. Alejandria MM, Lansang MA, Dans LF, Mantaring JB (2002) Intravenous immunoglobulin for treating sepsis and septic shock. Cochrane Database Syst Rev (1):CD001090
34. Asakura H, Takahashi Y, Anna K, Ontachi Y, Hayashi T, Omote M, Arahata M, Kadohira Y, Maekawa M, Yamazaki M, Morishita E, Takami A, Yoshida T, Miyamoto K, Nakao S (2006) Immunoglobulin preparations attenuate organ dysfunction and hemostatic abnormality by suppressing the production of cytokines in lipopolysaccharide-induced disseminated intravascular coagulation in rats. Crit Care Med 34:2421-2425 (Pubitemid 44260029)